Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Update

Clearmind Medicine Inc. (NASDAQ:CMND) was the target of a large decrease in short interest during the month of March. As of March 13th, there was short interest totaling 64,024 shares, a decrease of 37.9% from the February 26th total of 103,059 shares. Based on an average daily volume of 147,708 shares, the short-interest ratio is currently 0.4 days. Currently, 4.3% of the shares of the stock are short sold.

Clearmind Medicine Stock Performance

NASDAQ CMND opened at $0.81 on Friday. The stock has a 50 day moving average price of $1.39 and a 200-day moving average price of $14.22. Clearmind Medicine has a one year low of $0.59 and a one year high of $52.40. The company has a market capitalization of $1.22 million, a P/E ratio of -0.04 and a beta of 1.51.

Clearmind Medicine (NASDAQ:CMND) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($3.32) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised Clearmind Medicine to a “sell” rating in a report on Saturday, December 20th.

Institutional Trading of Clearmind Medicine

A hedge fund recently raised its stake in Clearmind Medicine stock. AdvisorShares Investments LLC grew its holdings in shares of Clearmind Medicine Inc. (NASDAQ:CMND) by 9.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 224,378 shares of the company’s stock after buying an additional 18,445 shares during the quarter. AdvisorShares Investments LLC owned 4.10% of Clearmind Medicine worth $230,000 at the end of the most recent reporting period. 96.05% of the stock is currently owned by institutional investors and hedge funds.

About Clearmind Medicine

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.